Skip to main content

Biosearch Acquires Rights to TurboFish Technology

NEW YORK (GenomeWeb News) – Biosearch Technologies today announced it has acquired the exclusive worldwide rights to the turboFISH technology.

As a result, the Petaluma, Calif.-based firm maintains exclusive access to continuing Stellaris RNA FISH-based inventions from Rutgers University, it said.

TurboFish is a method for rapid single molecule RNA FISH. In a statement, Marc Beal, director of corporate development and licensing at Biosearch, said, "Point-of-care, point-of-contact, hospital bedside, and immediate care facilities are now target markets for real-time gene expression analysis using turboFISH. Extending turboFISH into the [operating room] for intraoperative analysis may allow for real-time cancer diagnostics, eliminating the need, ambiguities, and procedure of formalin fixation and paraffin embedding tissues for days-later analysis."

Financial and other terms of the deal were not disclosed.

Biosearch recently acquired a majority stake in LightSpeed Genomics. The two firms are co-developing a gene expression platform, optimized to work on Stellaris RNA FISH assays for detecting and quantifying single molecular RNA targets within individual cells.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.